why choose us

First received: April 01, 2023

Clinical Trial: Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Lymphocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: A Phase I Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T- Cells for Treating B-cell Malignancies

Brief Summary: Background:About 23,000 people die from B-cell cancers in the US each year.These cancers, often called leukemia or lymphoma, affect a type of white blood cell called B cells.These cancers are difficult to treat, and the therapies used can have bad side effects.Researchers want to try a new type of treatment.This new treatment uses a patient s own immune cells (T cells) that are modified to carry genes (chimeric antigen receptor, or CAR T cells) to kill cancer cells.Objective:To test a treatment using CAR T cells…

Read more